| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/LIV.13265 |
| P698 | PubMed publication ID | 27712010 |
| P2093 | author name string | Jean-Louis Frossard | |
| Olivier Chazouillères | |||
| Sophie Restellini | |||
| P2860 | cites work | Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community | Q47404936 |
| Gallstone disease and related risk factors in patients with Crohn disease: analysis of 330 consecutive cases | Q50180885 | ||
| Evaluation of liver fibrosis by transient elastography (Fibroscan®) in patients with inflammatory bowel disease treated with methotrexate: a multicentric trial. | Q50519343 | ||
| Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis. | Q50542465 | ||
| East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. | Q51212363 | ||
| Diagnosis and management of primary sclerosing cholangitis. | Q51726466 | ||
| Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients. | Q51916542 | ||
| Incidence, diagnosis, and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis. | Q51989128 | ||
| Diagnosis of primary sclerosing cholangitis: a blinded comparative study using magnetic resonance cholangiography and endoscopic retrograde cholangiography. | Q53007468 | ||
| Atrophy and neoplastic transformation of the ileal pouch mucosa in patients with ulcerative colitis and primary sclerosing cholangitis: a case control study. | Q53378911 | ||
| Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. | Q53502601 | ||
| CT depiction of portal vein thrombi after creation of ileal pouch-anal anastomosis. | Q53657557 | ||
| Evolution of autoimmune hepatitis to primary sclerosing cholangitis: A sequential syndrome. | Q53949526 | ||
| Pediatric ulcerative colitis associated with autoimmune diseases: a distinct form of inflammatory bowel disease? | Q54329786 | ||
| EASL Clinical Practice Guidelines: management of cholestatic liver diseases. | Q55051951 | ||
| Portomesenteric vein thrombosis in patients with inflammatory bowel disease | Q57643472 | ||
| Incidence and risk factors for gallstones in patients with inflammatory bowel disease: A large case-control study | Q57972003 | ||
| Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis | Q24541353 | ||
| Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine | Q24564758 | ||
| High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis | Q24655731 | ||
| Use of biologics and chemotherapy in patients with inflammatory bowel diseases and cancer | Q26750190 | ||
| Hepatic manifestations of non-steroidal inflammatory bowel disease therapy | Q26773684 | ||
| Hepatobiliary manifestations of ulcerative colitis: an example of gut-liver crosstalk | Q26829300 | ||
| Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases | Q26864098 | ||
| Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review article | Q28076892 | ||
| Sulfasalazine-induced fulminant hepatic failure | Q28327415 | ||
| Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease | Q28362619 | ||
| Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet | Q28574910 | ||
| EASL clinical practice guidelines: Management of chronic hepatitis B virus infection | Q29615868 | ||
| Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. | Q30416155 | ||
| Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis | Q30592294 | ||
| Primary sclerosing cholangitis and the microbiota: current knowledge and perspectives on etiopathogenesis and emerging therapies | Q31170968 | ||
| Extraintestinal manifestations of inflammatory bowel disease: epidemiology, diagnosis, and management | Q33532262 | ||
| Autoimmune overlap syndromes | Q34205699 | ||
| Risk of natalizumab-associated progressive multifocal leukoencephalopathy | Q34275329 | ||
| Liver disease in ulcerative colitis: an epidemiological and follow up study in the county of Stockholm | Q34378444 | ||
| Importance of antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and ulcerative colitis: prevalence, titre, and IgG subclass | Q34409444 | ||
| Epidemiology and individual susceptibility to adverse drug reactions affecting the liver | Q34643107 | ||
| The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases | Q34985803 | ||
| Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL, and CARD9 | Q35062213 | ||
| Primary biliary cirrhosis and ulcerative colitis: a case report and review of literature | Q35101366 | ||
| Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis | Q35352934 | ||
| Cancer surveillance in patients with primary sclerosing cholangitis | Q35490961 | ||
| Cholecystectomy in Patients With Crohn's Ileitis | Q35578926 | ||
| Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population | Q35595032 | ||
| Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines | Q35595076 | ||
| Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? | Q35596373 | ||
| PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis | Q35597119 | ||
| Concurrent systemic AA amyloidosis can discriminate primary sclerosing cholangitis from IgG4-associated cholangitis | Q35670473 | ||
| Is gallstone disease associated with inflammatory bowel diseases? A meta-analysis | Q35762293 | ||
| Liver abscess in inflammatory bowel disease: report of two cases and review of the literature | Q35989530 | ||
| Thrombosis and inflammatory bowel disease | Q36277417 | ||
| Development of primary biliary cirrhosis in a patient with Crohn's disease: a case report and review of the literature | Q36369982 | ||
| Use of Methotrexate in the Treatment of Inflammatory Bowel Diseases | Q36372720 | ||
| Nonalcoholic fatty liver disease: from steatosis to cirrhosis | Q36382279 | ||
| Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review | Q36772955 | ||
| Immunoglobulin G4 associated cholangitis: description of an emerging clinical entity based on review of the literature | Q36835627 | ||
| Current treatments of primary sclerosing cholangitis. | Q36907309 | ||
| Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease | Q37058852 | ||
| Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis | Q37277424 | ||
| Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver. | Q37317444 | ||
| Late onset ulcerative colitis complicating a patient with Budd-Chiari syndrome: a case report and review of the literature. | Q37342672 | ||
| Reactivation of hepatitis B. | Q37462566 | ||
| Infliximab-related hepatitis: discussion of a case and review of the literature. | Q37682683 | ||
| Changes in liver biochemistry during methotrexate use for inflammatory bowel disease | Q37693666 | ||
| Small-duct primary sclerosing cholangitis | Q37755861 | ||
| Relationship of inflammatory bowel disease and primary sclerosing cholangitis | Q37755868 | ||
| A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. | Q37814549 | ||
| Hepatosplenic T-cell lymphoma and inflammatory bowel disease | Q37814566 | ||
| Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis | Q37847100 | ||
| Hepatobiliary disorders and complications of inflammatory bowel disease | Q37905969 | ||
| Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations | Q38049779 | ||
| Anti-TNF antibodies in inflammatory bowel disease: do we finally know how it works? | Q38102784 | ||
| Systematic review: The epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease. | Q38210793 | ||
| American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy | Q38275214 | ||
| American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. | Q38275215 | ||
| The natural history of small-duct primary sclerosing cholangitis | Q38457100 | ||
| Clinical Presentation and Outcomes of Autoimmune Hepatitis in Inflammatory Bowel Disease | Q38496932 | ||
| Natalizumab-induced hepatic injury: A case report and review of literature | Q38641614 | ||
| Genetics and Pathogenesis of Inflammatory Bowel Disease | Q38747192 | ||
| Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease. | Q39630894 | ||
| Prevalence of Sclerosing Cholangitis Detected by Magnetic Resonance Cholangiography in Patients With Long-term Inflammatory Bowel Disease | Q39656708 | ||
| Alcohol binging causes peliosis hepatis during azathioprine therapy in Crohn's disease | Q40179272 | ||
| Hepatic granulomas in Northern Ireland: a thirteen year review | Q40569812 | ||
| Increased risk of early colorectal neoplasms after hepatic transplant in patients with inflammatory bowel disease | Q40861860 | ||
| Pyogenic liver abscess in patients with inflammatory bowel disease: a nationwide cohort study | Q40900464 | ||
| New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease | Q41256627 | ||
| Liver disorders in inflammatory bowel disease | Q42122089 | ||
| Detection of liver injury in IBD using transient elastography | Q42228367 | ||
| Cholestatic hepatocellular injury with azathioprine: a case report and review of the mechanisms of hepatotoxicity | Q42538334 | ||
| Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. | Q42793428 | ||
| Genetic epidemiology of primary sclerosing cholangitis | Q42909560 | ||
| Mesalazine (5-aminosalicylic acid) induced chronic hepatitis | Q43086987 | ||
| Prevalence of metabolic syndrome is comparable between inflammatory bowel disease patients and the general population | Q43087820 | ||
| Inflammatory bowel disease and hepatitis B and C. | Q43458103 | ||
| Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis | Q43500799 | ||
| Ileal pouch-anal anastomosis and liver transplantation for ulcerative colitis complicated by primary sclerosing cholangitis | Q43637205 | ||
| Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study | Q43683228 | ||
| Inflammatory bowel disease is associated with poor outcomes of patients with primary sclerosing cholangitis | Q43878406 | ||
| 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. | Q43928996 | ||
| The use of methotrexate for treatment of inflammatory bowel disease in clinical practice | Q44261548 | ||
| Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study | Q44355973 | ||
| Simplified criteria for the diagnosis of autoimmune hepatitis | Q44425899 | ||
| Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease | Q44797986 | ||
| Pathologic features of ulcerative colitis in patients with primary sclerosing cholangitis: a case-control study | Q45001248 | ||
| Acute sinusoidal obstruction syndrome after 6-thioguanine therapy for Crohn's disease | Q45096831 | ||
| Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis | Q45103515 | ||
| Liver and inflammatory bowel disease. | Q46037068 | ||
| Hepatotoxicity of 6-mercaptopurine (6-MP) and Azathioprine (AZA) in adult IBD patients | Q46214775 | ||
| Severe hepatotoxicity with high 6-methylmercaptopurine nucleotide concentrations after thiopurine dose escalation due to low 6-thioguanine nucleotides | Q46260808 | ||
| Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome | Q46572197 | ||
| Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease | Q46753163 | ||
| A systematic survey evaluating 6-thioguanine-related hepatotoxicity in patients with inflammatory bowel disease | Q46944787 | ||
| 6-thioguanine associated nodular regenerative hyperplasia in patients with inflammatory bowel disease may induce portal hypertension | Q46982269 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 475-489 | |
| P577 | publication date | 2016-10-06 | |
| P1433 | published in | Liver International | Q15765078 |
| P1476 | title | Hepatic manifestations of inflammatory bowel diseases | |
| P478 | volume | 37 |
| Q92570415 | Comorbidities in inflammatory bowel disease: a call for action |
| Q64242255 | Frequency of Hepatobiliary Manifestations and Concomitant Liver Disease in Inflammatory Bowel Disease Patients |
| Q55114620 | Hepatobiliary Manifestations and Complications in Inflammatory Bowel Disease: A Review. |
| Q49806997 | Increased cholestatic enzymes in two patients with long-term history of ulcerative colitis: consider primary biliary cholangitis not always primary sclerosing cholangitis |
| Q49959033 | Neutralization of IL-15 abrogates experimental immune-mediated cholangitis in diet-induced obese mice |
| Q60956429 | Pediatric Fatty Liver and Obesity: Not Always Justa Matter of Non-Alcoholic Fatty Liver Disease |
| Q104472228 | The Impact of Biologics for the Management of Inflammatory Bowel Disease on Liver Enzymes |
Search more.